Table.

Efficacy of EGFR TKIs in Patients with Non-small-cell Lung Cancer with EGFR Exon 20 Insertion.

Reference	EGFR exon 20 insertions/ total lung cancers tested (%)	EGFR exon 20 insertions/ all EGFR mutations (%)	TKI solo treatment (n)	Objective response rate (%)	PFS with EGFR TKI (months)	Median OS (months)
(9)	7/332 (2.1%)	7/54 (13.0%)	2 (Gef)	0	N/A	N/A
(10)	13/515 (2.5%)	13/253 (5.1%)	2 (Gef)	0	1.6	N/A
(11)	N/A	3/222 (1.4%)	3 (Gef or Erl)	0	1.0	1.5
(12)	N/A	7/119 (5.9%)	4 (2; Gef, 2; Erl)	0	N/A	N/A
(13)	27/1,086 (2.5%)	27/294 (9.2%)	8 (Erl)	0 (n=0/5)	2.4	16.5
(14)	33/1,500 (2.2%)	33/367 (9.0%)	2 (Erl)	0	N/A	>48 (n=15)
(15)	41/1,047 (3.9%)	41/1,047 (3.9%)	19 (Erl or Gef)	5.3 (n=1/19)	N/A	N/A
(16)	46/1,882 (2.4%)	N/A	11 (Erl)	27 (n=3/11)	2.5	26
(3)	N/A	23/600 (3.8%)	23 (Afa)	8.7 (n=2/23)	2.7	9.2
(17)	29/3,910 (0.74%)	29/1,560 (1.9%)	29 (Erl or Gef or Ico)	6.9 (n=2/29)	1.9	12.9

EGFR: epidermal growth factor receptor, TKI: tyrosine kinase inhibitor, PFS: progression-free survival, OS: overall survival, PR: partial response, Gef: gefitinib, Erl: erlotinib, Afa: afatinib, Ico: icotinib, N/A: not available